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Abstract 
The LREX' prostate cancer model is resistant to the antiandrogen enzalutamide via activation of an alternative 
nuclear hormone receptor (NHR), glucocorticoid receptor (GR), which has similar DNA binding specificity to the 
androgen receptor (AR). Small molecules that target DNA to interfere with protein-DNA interactions may retain 
activity against enzalutamide-resistant prostate cancers where ligand binding domain antagonists are 
ineffective. We reported previously that a pyrrole-imidazole (Py-Im) polyamide designed to bind the consensus 
androgen response element half-site has antitumor activity against hormone-sensitive prostate cancer. In 
enzalutamide-resistant LREX' cells, Py-Im polyamide interfered with both androgen receptor- and 
glucocorticoid receptor-driven gene expression, while enzalutamide interfered with only that of androgen 
receptor. Genomic analyses indicated immediate interference with the androgen receptor transcriptional 
pathway. Long-term treatment with Py-Im polyamide demonstrated a global decrease in RNA levels consistent 
with inhibition of transcription. The polyamide was active against two enzalutamide-resistant xenografts with 
minimal toxicity. Overall, our results identify Py-Im polyamide as a promising therapeutic strategy in 
enzalutamide-resistant prostate cancer. 
  
on April 3, 2017. © 2017 American Association for Cancer Research. cancerres.aacrjournals.org Downloaded from 
Author manuscripts have been peer reviewed and accepted for publication but have not yet been edited. 
Author Manuscript Published OnlineFirst on March 30, 2017; DOI: 10.1158/0008-5472.CAN-16-2503 
  3
Introduction 
Prostate cancer (CaP) is the second leading cause of cancer death in American men with 26,000 deaths 
annually (1), the majority from metastatic, castrate resistant CaP (mCRPC), in which androgen deprivation 
therapy (ADT), which suppresses AR signaling, is ineffective. Enzalutamide, a potent AR-ligand binding 
domain (LBD) antagonist, is effective against mCRPC and is a current standard of care (2). Unfortunately, de 
novo or acquired resistance to enzalutamide is common (3); overcoming this is an unmet need. 
Mechanisms of enzalutamide resistance include restoration of AR signaling through LBD mutations or 
expression of transcriptionally active splice variants lacking the LBD (4), bypass of AR signaling through 
alternative NHRs (5), or development of complete independence from AR signaling (6). GR is a NHR with a 
sequence preference similar to AR (7). After enzalutamide treatment, the LREX’ cell line highly expresses GR, 
which drives enzalutamide resistance by regulating gene expression significantly overlapping that of AR, 
suggesting CaPs co-opt GR to progress through AR antagonism (5).  Furthermore, GR expression in mCRPC 
associates with poor response to enzalutamide (5). Therefore, interference with the NHR-DNA interface may 
overcome enzalutamide resistance.  
A Py-Im polyamide (ARE-1) is effective against hormone sensitive LNCaP xenografts with minimal host toxicity 
(8). Py-Im polyamides are minor groove DNA binding small molecules with modular sequence specificity and 
high affinity (9). Polyamide-DNA binding induces widening of the minor groove and compression of the 
opposing major groove (10), interfering with transcription factor-DNA interactions and the transcriptional 
machinery (11,12). A polyamide targeted to the ARE might prevent AR and GR signaling, and transcription.   
We hypothesized that ARE-1 may be effective against enzalutamide-resistant CaP.  We report ARE-1 efficacy 
against enzalutamide resistant VCaP and LREX’ CaP models in cell culture and xenografts.  Mechanistic 
studies reveal immediate interference with androgen induced gene expression and reduced transcription after 
long-term treatment. 
Materials and Methods 
Cell culture conditions and cytotoxicity assays. The LREX’ and LNCaP/AR cell lines were gifts from 
Charles Sawyers (Memorial Sloan Kettering) and received 2014 and 2007, respectively. The VCaP cell line 
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was a gift from Kenneth Pienta (University of Michigan Medical School) and received 2012.  Cells were 
maintained as previously described (5,8,11–13), and were used within 10 passages from thawing. Cells were 
validated to parental cell lines by STR profile at IDEXXX Bioresearch following experimentation and confirmed 
to be Mycoplasma free.  WST-1 assay (Roche) was used to measure cytotoxicity.  Long-term toxicity in VCaP 
cells was assayed by cell counting.   
Confocal imaging.  Imaging was as described (8). Briefly, 2µM of ARE-1-FITC was added for 16hours, 
washed with PBS, and imaged on a Zeiss LSM 5 Exciter.  
Gene expression analysis.  LNCaP/AR and LREX’ cells were cultured for 72hours after plating in phenol-red 
free RPMI1640 (10% CT-FBS) in six well plates at 40,000 and 50,000cells/mL, respectively.  LNCaP/AR cells 
were treated with 10μM ARE-1, bicalutamide (bic), or enzalutamide (enz, Aurum Pharmatech) for an additional 
48, 2, and 2hours, respectively, prior to treatment with 1nM DHT or ethanol for 16hours.  LREX’ cells were 
treated with 10μM ARE-1 for 16hours prior to induction with 1nM DHT or 100nM dexamethasone (dex) for 
8hours. RNA extraction (RNEasy columns, Qiagen), cDNA generation (Transcriptor First Strand cDNA kit, 
Roche), and qRT-PCR (SYBR Green Master Mix, Applied Biosystems, ABI7300 instrument) were as described 
(8,11,12). Expression was normalized to β-glucuronidase. 
RNAseq analysis.  LREX’ cells were plated at 50,000cells/mL in 10cm2 dishes , treated with or without 10µM 
of ARE-1 in fresh media, incubated 16hours, and induced with 1nM DHT for 8hours.  Tumor samples were 
homogenized mechanically.  Total RNA was triazol extracted, sequenced (Illumina HiSeq2000), mapped 
against the human genome (hg19) with Tophat2 using Ensembl GRCh37 gene annotations.  Human and 
mouse reads from tumor samples were parsed with BBSplit and unique reads were mapped. Htseq-count was 
used for exon alignment and DESeq2 for differential expression. Gene set enrichment analysis (GSEA) was 
performed on genes with padj<0.05 and fold change≥1.6 for cell samples and padj<0.05 for tumor samples.  
Nascent RNA measurement.  LREX’ cells were plated at 100,000cells/mL in 96 well plates in RPMI1640 
(20% FBS and 1µM enz), adhered for 24hours, dosed with ARE-1, incubated for 48hours. The Click-iT® RNA 
Alexa Fluor® 488 HCS kit was used for dye conjugation and incorporation of 5-ethynyl uridine (5-EU) was 
measured on a Flexstation 3 plate reader. 
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Flow cytometry.  LREX’ cells were plated at 100,000cells/mL in 175cm2 flasks, adhered 24hours, incubated 
with 10µM ARE-1 24, 48, and 72hours, then with 300µM 5-EU in fresh media.  Cells were detached by 
Accumax or Accutase, and Alexa Fluor® 488 azide dye was conjugated.  Cells were passed through 35µm 
mesh prior to flow, sorted on a FACSCalibur instrument (Beckman-Dickinson), analyzed using FlowJo. 
Animal experiments. Animal experiments were performed at Caltech under IACUC approval. VCaP and 
LREX’ cells were engrafted as 1:1 mixtures of 3x106cells in Matrigel (BD Biosciences) into flanks of intact and 
castrated male SCID mice (Charles River), respectively.  LREX’ engrafted mice received 10mg/kg enz (oral 
gavage) daily. Once tumors were 100mm3 (0.5*l*w*w), ARE-1 was administered subcutaneously to opposing 
flanks in 20% DMSO:saline. For circulation studies, four C57BL6/J animals were injected subcutaneously with 
ARE-1 at 30mg/kg and blood collected retroorbitally. Plasma concentrations of ARE-1 were analyzed by 
HPLC, area under the curve (AUC) approximated by the linear trapezoidal method, as described (8). 
Immunohistochemistry. Tumors were fixed in neutral-buffered formalin, paraffinized, sectioned, stained as 
described (12).  Quantification of five random fields per slice was performed by ImmunoRatio.   
Statistical analysis. Cell culture experiments represent ≥3 independent biological replicates. Sequencing 
analyses were duplicates for cell culture and quadruplicates for tumor samples. For xenografts, animals were 
randomly assigned to groups. For circulation experiments, concentrations of ARE-1 were duplicate 
measurements. Measurements in cell culture, animal, and immunohistochemistry experiments were assessed 
by Student’s t-test. 
Results 
ARE-1 is more potent than enzalutamide against CaP cell growth and is not rescued by GR activation  
ARE-1 (Fig. 1A) targets the sequence 5`-WGWWCW-3` (W=A or T), similar to the consensus half site 
recognized by either AR or GR. Nuclear uptake in LNCaP/AR, LREX’, and VCAP cells was evaluated using 
fluorescent analog ARE-1-FITC (Supplementary Fig. S1). The LNCaP/AR cell line overexpresses full length 
AR, modeling castration resistance (14). ARE-1 reduced proliferation of LNCaP/AR cells more than 
bicalutamide (Fig. 1B). The VCaP cell line overexpresses AR with modest GR expression, the activation of 
which reduces the antiproliferative effects of enzalutamide (5). ARE-1 reduced proliferation of both VCaP and 
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LREX’ cells regardless of induction of AR signaling by 1nM DHT, induction of GR signaling by 100nM dex, or 
both (Fig. 1C-D). Long-term cell viability studies in VCaP cells show ARE-1 is more potent than enzalutamide 
and insensitive to GR activation (Fig. 1D).   
Py-Im polyamide attenuates androgen and glucocorticoid driven gene expression 
In androgen-depleted conditions, bicalutamide activates AR in the LNCaP/AR cell line (14). Enzalutamide and 
ARE-1 demonstrate no agonist activity; ARE-1 reduced baseline expression of KLK3 (Fig. 2A).  In LREX’ cells, 
ARE-1 represses KLK3 and HOMER2 expression, which are co-regulated by AR and GR (Fig. 2B).  While 
enzalutamide was more potent than ARE-1 in reducing DHT induced transcription, the opposite was observed 
with dex induction.  Furthermore, co-administration of enzalutamide and ARE-1 was additive, suggesting ARE-
1 may potentiate enzalutamide’s activity. 
Global transcriptomic effects of Py-Im polyamides  
We performed RNA-seq analysis on three treatment conditions in LREX’ cells: vehicle, DHT treatment, and co-
treatment with ARE-1 and DHT, and two conditions in parental LNCaP cells: vehicle, and ARE-1 treatment. 
GSEA of affected genes in LREX’ cells using the hallmark pathways in the Molecular Signatures Database 
revealed DHT treatment enriched for the AR signaling pathway as expected (Fig. 2C,  Supplementary Fig. S2 
and Table S1). DHT-induced LREX’ cells treated with ARE-1 negatively enriched for the AR signaling pathway 
(NES -3.875) (Fig. 2C, Supplementary Table S1), consistent with interference in AR-driven gene expression by 
ARE-1. Additionally, ARE-1 treatment negatively enriched for the UV DNA damage response pathway down 
(NES -4.310) (Fig. 2C). Similarly, ARE-1 treatment in LNCaP cells negatively enriched for the AR signaling 
pathway (NES -2.778) and the UV DNA damage response pathway down (NES -2.240) (Fig. 2D,  
Supplementary Table S1).  UV radiation induces DNA helical distortions through formation of pyrimidine dimers 
and 6-4 photoproducts, which arrest RNA Polymerase II (RNAP2) during elongation, triggering degradation of 
RPB1. ARE-1 reduced nascent RNA in LREX’ cells as measured by 5-EU incorporation (Fig. 3), and we have 
previously observed RPB1 degradation after long-term treatment with ARE-1 and related polyamides (8,12).  
This suggests long-term treatment with ARE-1 reduces global transcription in LREX’ cells. 
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Suppression of enzalutamide resistant, castrate resistant CaP in vivo 
We further tested the efficacy of ARE-1 in VCaP xenografts, which exhibit modest response to 10mg/kg 
enzalutamide treatment, and in mice engrafted with enzalutamide resistant LREX’ cells (5,13). In VCaP 
xenografts, ARE-1 dose-dependently reduced tumor growth by 70% at 5mg/kg compared to vehicle (Fig. 4A) 
without significant toxicity (Supplementary Fig. S3A). In castrated mice bearing LREX’ tumors, ARE-1 and 
enzalutamide cotreatment reduced growth by 80% compared to enzalutamide alone (Fig. 4B) without 
significant toxicity (Supplementary Fig. S3B). Enzalutamide was administered daily post engraftment at 
10mg/kg to maintain GR expression, which was confirmed by immunohistochemistry. LNCaP tumors, which do 
not express GR, were used as controls (Fig. 4C).  Furthermore, LREX’ tumors treated with ARE-1 and 
enzalutamide showed reduced KLK3 expression (Supplementary Fig. S3C), elevated TUNEL and reduced 
Ki67 staining compared to enzalutamide alone (Supplementary Fig. S3D). GSEA of tumor expression profiles 
show ARE-1 treatment elicits similar UV response signatures as seen in cell culture, and represses ontologies 
associated with DNA binding dependent transcription (Supplementary Tables S2 and S3).  Plasma 
concentration of ARE-1 from terminal blood samples from LREX’ engrafted animals was compared to the 
plasma concentration in C57BL6/J animals treated with 30mg/kg; AUC was 25.9 and 189.9µg*hr/mL, 
respectively (Supplementary Fig. S4). At 30mg/kg mice experienced a 6% weight loss but recovered within 5 
days without visible signs of distress (not shown). 
Discussion 
AR LBD mutations, expression of transcriptionally active splice variants lacking the LBD, co-option of NHRs 
with similar DNA binding specificities, or loss of reliance on AR, may drive enzalutamide resistance (3). 
Furthermore, different metastatic foci within a patient may resist enzalutamide through different mechanisms 
(15), suggesting a successful treatment strategy might use multiple therapeutics that overcome different 
resistance mechanisms, or alternatively, a single therapeutic capable of overcoming multiple mechanisms. 
Therapeutic targeting of the NHR-DNA interface may overcome most known enzalutamide resistance 
mechanisms. 
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The GR antagonist mifepristone added to ADT was previously tested in mCRPC patients and was not 
effective(16). Trials for mCRPC patients combining enzalutamide with mifepristone are underway. Other NHRs 
may also be active in refractory CaP (3).  Notably, progesterone receptor inhibitors have entered clinical trials 
for mCRPC.  Therapeutics targeting the N-terminal domain (NTD) of AR, or that mediate degradation of AR, 
may overcome treatment resistance due to AR splice variants. The NTD inhibitor EPI-506 has entered clinical 
trials (17). However, this approach may not overcome resistance due to co-option of alternate NHRs. Others 
have reported small molecules that interfere with the AR DNA-binding domain (18). The clinical utility of this 
approach is unknown.  
We report a Py-Im polyamide with activity against enzalutamide-resistant CaP in cell and animal models. 
Polyamide ARE-1, targeted to the sequence 5`-WGWWCW-3`, which is similar to the ARE and GRE half site, 
attenuates ligand induced AR and GR transcriptional activity, is more potent than enzalutamide and 
bicalutamide in cell culture, and is active against enzalutamide resistant xenografts. Long term treatment of 
LREX’ cells with ARE-1 also decreases nascent RNA synthesis. In biophysical experiments, polyamides can 
halt RNAP2 elongation directly upstream of a polyamide binding site (19). We hypothesize this stalling of 
RNAP2 promotes ubiquitination and degradation of RPB1, ultimately interfering with RNA synthesis, which 
may contribute to efficacy against treatment refractory CaP. Other molecules that interfere with RNA synthesis 
are proposed as potential drug candidates for CaP (13,20). 
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Figure 1. A, structure of ARE-1. B, cytotoxicity of ARE-1, Bic, and Enz in LNCaP/AR cells over 72hours.   C, 
cytotoxicity of ARE-1 in LREX’ cells is not attenuated by AR or GR activation. D, top, cytotoxicity of ARE-1 in 
VCaP cells is not affected by Dex, bottom, long-term incubation of ARE-1 or Enz in VCaP cells. Error bars are 
SEM. * p<0.05.  
Figure 2. A, effects of ARE-1, Bic, and Enz on DHT induced KLK3 mRNA in LNCaP/AR cells (top), and 
baseline (charcoal stripped media) (bottom). B, effects of ARE-1 and Enz against select genes co-regulated by 
AR and GR in LREX’ cells. C, GSEA analysis in LREX’ cells. Top, DHT enriches for the Androgen Response. 
Bottom, ARE-1 with DHT negatively enriches for Androgen Response and the UV Response Down. D, ARE-1 
treatment of LNCaP cells negatively enriches for Androgen Response and the UV Response Down. * p<0.05.  
Figure 3. A, nascent RNA in LREX’ cells treated with ARE-1 for 48hours.  Actinomycin D (Act D):positive 
control. B, nascent RNA in LREX’ cells by flow cytometry after treatment with 10μM ARE-1 for 24, 48, 72hours.  
C, composite of flow cytometry results. Error bars are SEM. *p<0.05; **p<0.005; ***p<0.0005. 
Figure 4. Mice were treated three times per week with ARE-1 subcutaneously to flanks opposite engrafted 
tumor. A, left, tumor volumes and (right) final tumor masses of VCaP xenografts treated with vehicle 
(Veh)(n=8), 2.5mg/kg(n=7), and 5mg/kg(n=8) ARE-1.  B, left, tumor volumes and (right) final tumor masses of 
LREX’ xenografts in castrated animals treated daily with 10mg/kg Enz and Veh(n=14) or Enz and 2.5mg/kg 
ARE-1(n=12).  C, GR staining of LREX’ and LNCaP tumors. All LREX’ tumors stained for GR. Error bars for 
tumor volumes are SEM. Whisker plots represent means, standard deviations. 
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